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The K + -Cl − cotransporter KCC2 is responsible for maintaining low Cl − concentration in neurons of the central nervous system (CNS), which is essential for postsynaptic inhibition through GABA A and glycine receptors. Although no CNS disorders have been associated with KCC2 mutations, loss of activity of this transporter has emerged as a key mechanism underlying several neurological and psychiatric disorders, including epilepsy, motor spasticity, stress, anxiety, schizophrenia, morphine-induced hyperalgesia and chronic pain [1] [2] [3] [4] [5] [6] [7] [8] [9] . Recent reports indicate that enhancing KCC2 activity may be the favored therapeutic strategy to restore inhibition and normal function in pathological conditions involving impaired Cl − transport [10] [11] [12] . We designed an assay for high-throughput screening that led to the identification of KCC2 activators that reduce intracellular chloride concentration ([Cl − ] i ). Optimization of a first-in-class arylmethylidine family of compounds resulted in a KCC2-selective analog (CLP257) that lowers [Cl − ] i . CLP257 restored impaired Cl − transport in neurons with diminished KCC2 activity. The compound rescued KCC2 plasma membrane expression, renormalized stimulus-evoked responses in spinal nociceptive pathways sensitized after nerve injury and alleviated hypersensitivity in a rat model of neuropathic pain. Oral efficacy for analgesia equivalent to that of pregabalin but without motor impairment was achievable with a CLP257 prodrug. These results validate KCC2 as a druggable target for CNS diseases.
To identify compounds that increase Cl − efflux, we developed a simple fluorometric assay to measure [Cl − ] i in real time. As a model, we chose the NG-108 cell line, which expresses low levels of KCC2 protein (Fig. 1a) , and into which we stably transfected the Cl − -sensitive indicator Clomeleon 13 , yielding NG108-cl cells. The low KCC2 activity of NG-108 cells mimics the pathophysiological situation in neuropathic pain. We calibrated and validated the fluorometric assay by placing NG108-cl and KCC2-lacking HEK293-cl cells [14] [15] [16] in isosmolar extracellular medium containing increasing Cl − concentration in permeabilized cells to clamp [Cl − ] i at different levels. We found a linear relationship between the fluorescence ratio and [Cl − ] i in both cell lines and determined a resting [Cl − ] i of 57.15 ± 2.43 mM (mean ± s.d.) for NG108-cl and 56.15 ± 2.73 mM ((mean ± s.d.) for HEK293-cl (Fig. 1b) . In nonpermeabilized NG108-cl cells, [Cl − ] i did not change with increasing extracellular chloride concentration ([Cl − ] e ), indicating little endogenous Cl − transport in these cells (Fig. 1a) . In contrast, [Cl − ] i was altered slightly in HEK293-cl when [Cl − ] e was elevated, consistent with their higher NKCC1 expression (Fig. 1a) . The fluorescence ratio within the range of [Cl − ] i tested was minimally affected by pH (Fig. 1b) . We then carried out highthroughput screening of a library of 92,500 drug-like 17 compounds to identify small molecules able to reduce [Cl − ] i and confirmed a total of 78 as positive hits. Many of these compounds could be grouped into chemical families sharing similar structures. We further selected hits for lack of effects on [Cl − ] i in HEK293-cl cells, which do not express KCC2 but do express NKCC1, KCC1, KCC3 and KCC4 (refs. 16,18) (Fig. 1a) . Further selection based on lack of cytotoxic effects, ease of synthesis and drug-like properties 17 identified the hit compound CL-058 for further characterization and optimization (Fig. 1c,d) .
We synthesized more than 300 unique analogs of CL-058 to improve potency and drug-like properties 17 . This lead optimization campaign defined a clear structure-activity relationship ( Supplementary Fig. 1 and Supplementary Table 1 ) and improved on the potency of CL-058 (half-maximum effective concentration (EC 50 ) = 31.5 µM) by almost 3 logs with compounds such as CLP355 (EC 50 = 50 nM; Fig. 1d ). We chose CLP257 (EC 50 = 616 nM) for further characterization because of its better chemical stability and overall properties, such as ease of synthesis, plasma protein binding and CYP inhibition. Maximal [Cl − ] i reduction by CLP257 was ~40%, a 23-mM drop from resting [Cl − ] i of 57 mM.
We found no change in [Cl − ] i in HEK293-cl cells when incubated with CLP257 (Fig. 1e) , which indicates CLP257 is inactive against NKCC1, KCC1, KCC3 or KCC4. Additionally, we performed a Rb + -flux assay of CLP257 selectivity in Xenopus laevis oocytes microinjected with cRNA coding for the various transporters of the cation chloride cotransporter (CCC) family (Fig. 1f) . Oocyte preincubation with CLP257 (200 nM) increased KCC2 transport activity by 61% (P < 0.01), but caused no change in other CCCs (Fig. 1f) . We also observed functional, dose-dependent antagonism between CLP257 and the recently characterized KCC2 antagonist VU0240551 (ref. 19) (Fig. 1g) . We also assessed the affinity of CLP257 for classical pharmacological targets using radioligand competition binding assays. Of the 55 radioligand-receptor interactions tested, none were inhibited by more than 30% at 10 µM CLP257 (Supplementary Table 2) . Notably, CLP257 (50 µM) provoked <0.2% of the effect of 5 µM muscimol in Chinese hamster ovary cells transduced with recombinant α 1 β 2 γ 2 GABA A receptors, indicating negligible agonist activity of CLP257 on GABA A receptors. Taken together, these data show that CLP257 reduces [Cl − ] i through selective modulation of KCC2.
We then tested whether CLP257 could reverse KCC2 hypofunction in mature neurons. We measured the effect of CLP257 on Cl − transport in spinal slices obtained from rats with peripheral nerve injury (PNI; as an experimental model of neuropathic pain) 20 and control slices pretreated with brain-derived neurotrophic factor (BDNF), which mediates downregulation of KCC2 activity 21, 22 in models of pain hypersensitivity 3, 9, [23] [24] [25] [26] [27] . We assessed the functioning of KCC2 by quantitatively measuring K + -driven Cl − influx via fluorescence lifetime measurements of the Cl − probe MQAE 10 (Fig. 2a-c) . Using abrupt elevation of [K + ] e to trigger KCC2-dependent Cl − influx, we found that CLP257 (25 µM) significantly increased the rate of Cl − accumulation in both BDNF-treated and PNI spinal slices by 26% and 45%, respectively ( Fig. 2d,e ; P < 0.05). At 100 µM, CLP257 completely restored Cl − transport to control levels in BDNF-treated slices. Thus, CLP257 effectively enhanced Cl − transport in CNS neurons with reduced KCC2 function.
We tested whether CLP257 modulates Cl − extrusion capacity using voltage-clamp recordings from superficial dorsal horn (SDH) neurons in spinal cord slices treated with BDNF and isolated from rats with PNI 3 . A Cl − load was imposed through the recording pipette to measure Cl − extrusion capacity via the reversal potential for GABA A currents (E GABA ) 9 . E GABA was depolarized in SDH neurons of BDNFtreated and PNI slices (Fig. 2f-h) . In both conditions, E GABA was hyperpolarized by 25 µM CLP257 (Fig. 2h) , reflecting an increase in neuronal Cl − extrusion capacity. Thus, CLP257 can restore Cl − extrusion capacity in neurons with reduced KCC2 activity 23 . The effects of CLP257 on E GABA were independent of changes in GABA A conductance, as acute application of CLP257 had no effect on evoked GABA A currents in the presence of the KCC2 antagonist VU0240551 (P > 0.05; Fig. 2i) .
To identify the mechanism by which CLP257 restored KCC2 activity, we immunoblotted for KCC2 protein in BDNF-pretreated rat npg spinal cord slices. We found that although total KCC2 expression was not significantly affected (P > 0.05), the cell surface expression of both KCC2 monomers and dimers was increased in CLP257-treated slices ( Fig. 3a,b ; P < 0.05). This indicates that CLP257 modulates plasmalemmal KCC2 protein turnover post-translationally. We tested the antinociceptive efficacy of CLP257 in PNI rats 3, 20, 28, 29 (Fig. 4a-d) . We measured evoked field electrophysiological responses in the superficial dorsal horn to graded mechanical stimuli of the hind foot. In naive animals, CLP257 had no effect on the stimulusresponse relationship over the entire range of stimulus intensity (2.5 to 135 g mm −2 ; Fig. 4a,c,d ). Evoked field responses were increased in animals with nerve injury ( Fig. 4d ; P < 0.05), but were renormalized by CLP257 (Fig. 4b,c,d ).
CLP257 also normalized mechanical withdrawal thresholds in PNI animals. Intraperitoneal (i.p.) administration of CLP257 increased withdrawal thresholds, peaking at 100 mg per kg body weight 2 h after injection (Fig. 4e) . Yet, the maximal analgesic effect of CLP257 was much weaker than that of gabapentin (Fig. 4e) . We hypothesized that a poor pharmacokinetic profile could limit CLP257 efficacy. Indeed, pharmacokinetic analysis revealed that the plasma concentration of CLP257 declines rapidly, with a terminal half-life (t 1/2 ) of <15 min (Fig. 4f) . Metabolite analyses revealed that the hydroxyl moiety of CLP257 rapidly undergoes glucuronidation (not shown) to produce an inactive metabolite (see CLP386, Supplementary Table 1) . 15 
npg
To improve the pharmacokinetics of CLP257, we designed a carbamate prodrug (CLP290) to protect the hydroxyl group from glucuronidation. The pharmacokinetic profile of CLP257 produced from the metabolism of CLP290 was much improved over that of native CLP257, with an apparent t 1/2 of 5 h and improved maximal plasma concentration and exposure (Fig. 4f) . The analgesic efficacy of CLP290 was also improved, with maximal oral efficacy equivalent to that of pregabalin, albeit at a higher dose (100 mg per kg body weight of CLP290 versus 30 mg per kg body weight of pregabalin; Fig. 4g ).
Pregabalin can cause sedation and dizziness, greatly affecting motor performance 30 . For comparison, we evaluated the motor impact of equipotent oral doses of CLP290 and pregabalin using an accelerating rotorod. Whereas pregabalin depressed motor function, CLP290 had no effect (Fig. 4h) . These results show that modulating [Cl − ] i produces analgesia without the motor side effects often seen with other analgesics.
To assess the toxicity of CLP290, we performed a 7-d repeat-dose study in rats, with a maximum daily dose of 2,000 mg per kg body weight. We observed no effect of CLP290 on clinical condition, body weight, food consumption, hematology, coagulation, clinical chemistry, urinalysis, organ weight, pathology or histopathology (Supplementary Table 3 ). The inhibition of hERG tail current, a common risk factor for cardiotoxicity, by CLP257 and CLP290 was weak and therefore of low risk (half-maximum inhibitory concentration 449 µM and 224 µM, respectively). Caspase-3 activation, a key process in apoptosis, was also not detected in rat hepatoma H4IIE cells in vitro after 24-h exposure to CLP257 at up to 300 µM (data not shown).
This work validates KCC2 as a druggable target and Cl − modulation as a new mechanism of action for the development of therapeutics (also see ref. 31 ). Expression of KCC2 is limited to the central nervous system, unlike the case for other CCCs that are expressed in several tissues 3, 12, [32] [33] [34] , such as the kidneys and blood vessels, where ionic homeostasis is important. This constrained expression makes KCC2 a prime target for the control of neuronal [Cl − ] i and should limit adverse side effects in other organs (for example, it is not expressed in choroid plexus, inner ear or sensory fibers 3, 12, 32, 33 ). In fact, unlike other KCCs (KCC1, KCC3 and/or KCC4), KCC2 is not involved in volume regulation and is not typically found in cells where these KCCs are expressed 12 .
The identification of a mechanism underlying neuropathic pain has allowed the development of this new class of compounds directly aimed at hypersensitivity. Drug development was previously limited by the poor understanding of the pathophysiology of neuropathic pain 35 , as reflected by the classes of currently approved drugs such as anticonvulsants 36 , antidepressants 37 and opioid narcotics 38 . As evidence is mounting that KCC2 dysfunction and Cl − homeostasis are central to many CNS disorders 1-8 , we believe that Cl − extrusion enhancers such as CLP257 and CLP290 represent an important new method of treatment for a wide range of neurological and psychiatric indications.
MeThOdS
Methods and any associated references are available in the online version of the paper. (c) Effect of CLP257 on the normalized maximal field response in control animals (Ctrl, n = 7 rats) and animals with peripheral nerve injury (PNI, n = 6 rats, W: 28, *P < 0.05). (d) Black bars: mean (± s.e.m.) maximal field responses to mechanical stimulation of the receptive field in control (Ctrl, n = 7 rats) and PNI rats (PNI, n = 6 rats, U: 4, *P < 0.05). Red bars: effect of CLP257 application in control (n = 7 rats) and PNI rats (n = 6 rats, W: 27, *P < 0.05). (e) Effect of CLP257 on paw withdrawal threshold in PNI rats. CLP257 was dissolved in 20% 2-hydroxypropyl-β-cyclodextrin (HPCD) and administered i.p. (means ± s.e.m.; n = 8-10; *P < 0.05, **P < 0.01; ***P < 0.001). BW, body weight. (f) Pharmacokinetic profile of CLP257 and the carbamate prodrug CLP290 in rats after intravenous (i.v.), i.p. or oral (p.o.) administration (means ± s.e.m.; n = 3 animals per time point). Inset: structure of CLP290. (g) Analgesic effect of CLP290 administered p.o. in a PNI rat (means ± s.e.m.; n = 7-32; *P < 0.05). (h) Effect of CLP290 and pregabalin (at equipotent analgesic dose) on motor performance in rats as measured by time spent on an accelerating rotorod (means ± s.e.m.; n = 4-12; U: 6; *P < 0.05).
npg 80-nm gold nanoparticle suspension to generate second-harmonic signal. Recorded cells were visually identified by merging transmitted light and MQAE fluorescence. Lifetime images were acquired every 10 s for a period of 7 min. After a control period of 50 s, perfusion solution was switched to ACSF containing 15 mM KCl (osmolarity adjusted using mannitol) to reverse KCC2-mediated Cl − transport 40 . Lifetime in each cell was averaged over the whole cell body area and extracted for each time point using custom-made Matlab software. Lifetime changes for each slice were then expressed as the mean of changes occurring in each cell. Briefly, based on the work of Digman et al. 41 , we converted the photon timing histograms of each acquired lifetime image to phasor plots. Then, for every time-point, regions of interest (ROIs) corresponding to cell bodies were selected and added to a new phasor. Lifetime of all the cells was averaged for each slice at each timepoint to generate the lifetime time course.
Electrophysiological recordings in rat spinal neurons. Whole-cell clamp recordings were performed in parasagittal slices of lumbar spinal cord from rats as described previously 9, 42, 43 . For experiments involving PNI rats, all recordings were made from slices ipsilateral to the nerve injury. In BDNF experiments, parasagittal spinal cord slices were incubated in BDNF (50 ng/ml) for >1 h before experimentation. For whole-cell experiments involving measurements of EGABA under Cl − load, borosilicate patch pipettes had a resistance of 4 to 5 MΩ when filled with a potassium methylsulfate-based intrapipette solution 9, 43 . Data were filtered during acquisition with a lowpass filter set at 2 kHz and sampled at 10 kHz using pClamp 10 (Molecular Devices). Data analysis was performed offline with Clampfit 10.2 (Molecular Devices). All recordings were performed at physiological temperature (30-34 °C) in standard ACSF 9, 42 supplemented with 10 mM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), 40 mM d-(−)-2-amino-5-phosphonovaleric acid (AP5) and 1 mM TTX. In experiments with BDNF-treated slices, the ACSF was supplemented with 50 ng ml −1 BDNF. To study the effects of CLP257 on GABA A receptor function, a CsCl-based intrapipette solution 42, 44 was used and the ACSF was supplemented with the KCC2 inhibitor VU0240551 (10 µM; Tocris Cookson, Ellisville, MO). GABA (1 mM) was puffed approximately 10 µm from the center of the soma for 30 ms. Only neurons with stable access resistance were included for subsequent analysis. Experimental E GABA was extrapolated from the GABA A I-V relationships.
Nerve injury models and behavioral testing. Under isoflurane anesthesia (induction at 4%, maintenance at 2%), a polyethylene cuff (PNI) 20, 28 or loose chromic gut ligatures (CCI) 29 were implanted around the left sciatic nerve of 190-to 200-g male Sprague-Dawley rats. Mechanical allodynia was quantified by assessing the paw withdrawal threshold using von Frey filaments (Stoelting, USA) using the up and down method 45 . Animals were classified as allodynic when their paw withdrawal thresholds were below 2 g (PNI) or 5 g (CCI) for at least two consecutive days after a constant decrease for >10 days post-surgery. Allodynia was measured before dosing (baseline) on the test day, and then animals received an intraperitoneal dose of vehicle (20% 2-hydroxypropyl-β-cyclodextrin), CLP257 or gabapentin, or an oral dose of vehicle, CLP290 or pregabalin. Pregabalin was preferred to gabapentin for comparison with CLP290 because it has more predictable pharmacokinetics and pharmacodynamics than gabapentin when given orally.
Evoked field electrophysiological recordings in the superficial dorsal horn. Laminectomies were performed in control and PNI rats (350-450 g) to expose the L4-S1 segments of the spinal cord under isoflurane anesthesia (induction at 4%, maintenance at 2%). To reduce breathing artifacts, the animals were paralyzed with pancuronium bromide (Sigma, USA) and ventilated artificially (SAR-830, CWE, USA). Expired CO 2 and body temperature were maintained at 4% and 37 °C. The rat was placed in a stereotaxic and spinal frame with two clamps fixed on its vertebra to immobilize the spinal cord. A spinal perfusion chamber, continuously perfused with sterile heated (35 °C) buffered saline (10 mM HEPES, Sigma-Aldrich, USA), was created by cutting a window in a solidified 4% agar bloc. For drug applications CLP257 was diluted in buffered saline from a DMSO stock solution to a final concentration of 100 µM (0.1% DMSO) and perfused for 30 min before subsequent measurements were performed to ensure that stable concentrations were reached within the tissue. 4 µM TTX (Sigma/RBI) was used as a control to abolish field responses. A locally designed, automatically controlled, force-feedback mechanical stimulator was used to apply graded and stable mechanical stimulations on the glabrous skin of the paw. Eight or nine graded step pressures covering a large range from non-noxious to noxious stimulation (5-140 g (mm −2 ) were used with a 2-mm 2 tip. A 2-4 min recovery period was allowed between stimuli to minimize sensitization. In vivo field recordings using a glass electrode (1-3 MΩ) were obtained from the superficial section of the dorsal horn (300 µm) that receives input from the glabrous skin of the hind paw. A glass electrode (1-3 MΩ) was mounted on a motorized micromanipulator (Burleigh 6000, USA). The signal was amplified (ER-1 Cygnus Technology, USA), filtered at 0.002-2 KHz, digitized at 20 KHz with a Power1401mkII (CED, UK) and analyzed with Spike2 (CED, UK). To evaluate the effect of the mechanical stimulations, we analyzed the area under the curve of the field response generated by the different stimuli. Field area was normalized to the maximal control response for each cell and averaged.
Pharmacokinetic analysis. CLP257 and CLP290 (in 20% 2-hydroxypropyl-β-cyclodextrin) were administered i.v., i.p. or p.o. to adult male SpragueDawley rats. Blood samples were collected from the saphenous vein before dosing and 0.25, 0.5, 1, 2, 4 and 7 h after dosing. Each blood sample (approximately 0.5 ml) was collected into a tube containing an anticoagulant (Na 2 -EDTA). Samples were kept on ice until centrifugation. The plasma obtained from each sample was recovered and stored frozen (at −80 °C) pending analysis by LC/MS.
Rotorod assay. Baseline motor performance was measured on the day of the test, before administration of test compounds, using an accelerating rotorod (IITC). Time on rod was assayed twice for each animal. CLP290 (in 20% 2-hydroxypropyl-β-cyclodextrin), pregabalin (in 0.9% NaCl) or vehicle (20% 2-hydroxypropyl-β-cyclodextrin) was then administered orally. Rotorod performance was measured again 2 h after dosing. Results are expressed as percentage of pre-dose time on rod for each group of animals.
Competitive binding assays. The competitive binding inhibition of 10 µM CLP257 for a number of receptor systems was assessed using validated radioligand competition binding assays under conditions defined by the contractor. Additional information on the assay conditions can be obtained from the contractor's website (http://www.cerep.fr/).
GABA A receptor automated whole-cell patch-clamp. The effect of CLP257 on GABA A receptor function was assessed using validated automated patchclamp assays under conditions defined by the contractor. Additional information on the assay conditions can be obtained from the contractor's website (http://www.cerep.fr/).
Toxicological studies. CLP290 (200, 600 and 2,000 mg per kg body weight per day) and vehicle (20% Captisol) control were administered twice daily by gavage to Sprague-Dawley rats (five males and five females per dose level) for 7 consecutive days. Mortality checks, clinical signs, food consumption and body weights were observed during treatment. At the end of treatment, animals were food-deprived overnight and then urine was collected for urinalysis. Terminal blood was collected from the abdominal aorta for clinical pathology evaluations followed by necropsy. Blood collected in EDTAcontaining tubes was evaluated for complete blood count. Blood collected in citrate-containing tubes was analyzed for activated partial thromboplastin time and prothrombin time. Blood collected in tubes containing clottingactivator gel was analyzed for comprehensive metabolic panel, A/G ratio (calculated), cholesterol (total), globulin (calculated), phosphorus (inorganic) and triglycerides. Urine was analyzed for bilirubin, blood, color and appearance, glucose, ketones, microscopic analysis, pH, protein, specific gravity, urobilinogen and volume. Adrenal glands, brain, heart, kidneys, liver, lungs, ovaries, pituitary gland, prostate, spleen, testes, thymus, thyroid with parathyroids and uterus were trimmed free of fat and weighed. Paired organs were weighed together, and organ weight was normalized to terminal body
